|Bid||0.813 x 100|
|Ask||1.090 x 500|
|Day's Range||0.946 - 0.988|
|52 Week Range||0.860 - 1.470|
|PE Ratio (TTM)||3.06|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2.15|
NEW YORK, NY / ACCESSWIRE / September 8, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.
VIVUS, Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced ...